Furthermore, our data demonstrate that the continued inhibition of HIF-1α can result in prolonged viral replication, highlighting the potential unwanted side effects associated with the use of HIF-modulating therapeutics in the context of other diseases, such as cancer. This evidence concerns the gene HIF1A and cancer.